Literature DB >> 15016800

CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells.

Carsten Scheller1, Anett Ullrich, Kirsty McPherson, Barbara Hefele, Johanna Knöferle, Stefan Lamla, Anke R M Olbrich, Hartmut Stocker, Keikawus Arasteh, Volker ter Meulen, Axel Rethwilm, Eleni Koutsilieri, Ulf Dittmer.   

Abstract

CpG oligodeoxynucleotides (CpG ODNs) stimulate immune cells via the Toll-like receptor 9 (TLR9). In this study, we have investigated the effects of CpG ODNs on latent human immunodeficiency virus (HIV) infection in human T cells. Treatment of the latently infected T cell line ACH-2 with CpG ODNs 2006 or 2040 stimulated HIV replication, whereas no effects were evident when ODNs without the CpG motif were used. CpG-induced virus reactivation was blocked by chloroquine, indicating the involvement of TLR9. In contrast to the responsiveness of ACH-2 cells, CpG ODNs failed to activate HIV provirus in the latently infected Jurkat clone J1.1. We also studied the effects of CpG ODNs on productive HIV infection and found enhancement of viral replication in A3.01 T cells, whereas again no stimulating effects were observed in Jurkat T cells. CpG ODN treatment activated NF-kappaB in ACH-2 cells, which was similarly triggered in uninfected A3.01 T cells following exposure to CpG ODNs, indicating that TLR9-induced signal transduction was not dependent on proviral infection. Our study demonstrates that CpG ODNs directly trigger the activation of NF-kappaB and reactivation of latent HIV in human T cells. Our results point to a novel role for CpG ODNs as stimulators of HIV replication and open new avenues to eradicate the latent viral reservoirs in HIV-infected patients treated with antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016800     DOI: 10.1074/jbc.M311609200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Supernatants from oral epithelial cells and gingival fibroblasts modulate human immunodeficiency virus type 1 promoter activation induced by periodontopathogens in monocytes/macrophages.

Authors:  O A González; J L Ebersole; C B Huang
Journal:  Mol Oral Microbiol       Date:  2010-04       Impact factor: 3.563

Review 2.  Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.

Authors:  Weizao Chen; Tianlei Ying; Dimiter S Dimitrov
Journal:  Expert Opin Biol Ther       Date:  2013-01-07       Impact factor: 4.388

Review 3.  Cancer therapies in HIV cure research.

Authors:  Thomas A Rasmussen; Jenny L Anderson; Fiona Wightman; Sharon R Lewin
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

4.  The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques.

Authors:  Yichuan Wang; Kristina Abel; Katherine Lantz; Arthur M Krieg; Michael B McChesney; Christopher J Miller
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Neisseria gonorrhoeae enhances HIV-1 infection of primary resting CD4+ T cells through TLR2 activation.

Authors:  Jian Ding; Aprille Rapista; Natalia Teleshova; Goar Mosoyan; Gary A Jarvis; Mary E Klotman; Theresa L Chang
Journal:  J Immunol       Date:  2010-02-10       Impact factor: 5.422

Review 6.  Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions.

Authors:  Nadia T Sebastian; Kathleen L Collins
Journal:  Expert Rev Anti Infect Ther       Date:  2014-09-04       Impact factor: 5.091

7.  Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus.

Authors:  Amanda B Macedo; Rachel S Resop; Laura J Martins; Matthew A Szaniawski; Eric S Sorensen; Adam M Spivak; Douglas F Nixon; R Brad Jones; Vicente Planelles; Alberto Bosque
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-10       Impact factor: 2.205

8.  Toll-like receptor expression and activation in astroglia: differential regulation by HIV-1 Tat, gp120, and morphine.

Authors:  Nazira El-Hage; Elizabeth M Podhaizer; Jamie Sturgill; Kurt F Hauser
Journal:  Immunol Invest       Date:  2011-03-22       Impact factor: 3.657

9.  Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.

Authors:  Amanda B Macedo; Camille L Novis; Caroline M De Assis; Eric S Sorensen; Paula Moszczynski; Szu-Han Huang; Yanqin Ren; Adam M Spivak; R Brad Jones; Vicente Planelles; Alberto Bosque
Journal:  JCI Insight       Date:  2018-10-04

10.  TLR3 and TLR4 are innate antiviral immune receptors in human microglia: role of IRF3 in modulating antiviral and inflammatory response in the CNS.

Authors:  Hyeon-Sook Suh; Meng-Liang Zhao; Namjong Choi; Thomas J Belbin; Celia F Brosnan; Sunhee C Lee
Journal:  Virology       Date:  2009-07-30       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.